Trial Profile
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs DNL-201 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 08 Jan 2021 According to a Denali Therapeutics Inc media release, data from this trial will be presented at upcoming medical congresses.
- 16 Sep 2020 Results evaluating safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson's disease (PD) patients presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 14 Jan 2020 Results presented in a Denali Therapeutics media release.